Illumina (ILMN) Rating Reiterated by Piper Jaffray Companies

Piper Jaffray Companies restated their buy rating on shares of Illumina (NASDAQ:ILMN) in a research note released on Tuesday. They currently have a $269.00 target price on the life sciences company’s stock.

ILMN has been the topic of several other reports. Canaccord Genuity reiterated a buy rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Zacks Investment Research cut shares of Illumina from a buy rating to a hold rating in a research report on Tuesday, October 31st. Goldman Sachs Group reiterated a neutral rating and issued a $200.00 price target on shares of Illumina in a research report on Tuesday, September 26th. Wells Fargo & Co upgraded Illumina from a market perform rating to an outperform rating and set a $205.00 price objective on the stock in a report on Tuesday, January 2nd. Finally, Janney Montgomery Scott upgraded Illumina from a sell rating to a neutral rating in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. Illumina has a consensus rating of Buy and a consensus target price of $214.38.

Shares of Illumina (NASDAQ ILMN) traded up $4.68 during trading on Tuesday, reaching $244.72. 975,763 shares of the company’s stock traded hands, compared to its average volume of 900,526. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. Illumina has a 12-month low of $156.50 and a 12-month high of $245.96. The company has a market capitalization of $35,730.00, a PE ratio of 46.17, a PEG ratio of 3.13 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the previous year, the business earned $0.97 earnings per share. Illumina’s revenue for the quarter was up 17.6% compared to the same quarter last year. equities research analysts anticipate that Illumina will post 3.75 EPS for the current fiscal year.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at approximately $113,458,805.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Omead Ostadan sold 3,540 shares of Illumina stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.91, for a total value of $803,261.40. Following the transaction, the executive vice president now directly owns 26,827 shares in the company, valued at approximately $6,087,314.57. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,671 shares of company stock worth $29,485,768. Company insiders own 0.89% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ILMN. Winslow Capital Management LLC purchased a new position in Illumina during the 2nd quarter valued at about $211,584,000. Fred Alger Management Inc. grew its stake in Illumina by 611.9% during the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after acquiring an additional 548,030 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after acquiring an additional 527,548 shares in the last quarter. Capital World Investors grew its stake in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after acquiring an additional 410,000 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Illumina by 1,556.2% during the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after acquiring an additional 310,084 shares in the last quarter. 91.60% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2018/01/13/illumina-ilmn-rating-reiterated-by-piper-jaffray-companies.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply